Modalis Therapeutics Corp. (4883) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Trans Genic Inc.

Cyfuse Biomedical KK

Oncolys BioPharma, Inc.

OncoTherapy Science, Inc.

Carna Biosciences, Inc.

MEDINET Co., Ltd.

Chiome Bioscience, Inc.

Kidswell Bio Corp.

StemCell Institute

Stella Pharma Corp.

Modalis Therapeutics Corp.

Why is Modalis Therapeutics Corp. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Modalis Therapeutics Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Modalis Therapeutics Corp.

-100.0%

-0.79

67.77%

Japan Nikkei 225

43.52%

1.48

29.43%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-209.76%

EBIT to Interest (avg)

-958.93

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.07

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.20

EV to EBIT

-0.29

EV to EBITDA

-0.29

EV to Capital Employed

-44.82

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-65.04%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at JPY -944.46 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -111 %

-8What is not working for the Company

INTEREST(Q)

At JPY 6.95 MM has Grown at inf%

PRE-TAX PROFIT(Q)

At JPY -615.07 MM has Fallen at -35.23%

NET PROFIT(Q)

At JPY -621.36 MM has Fallen at -36.49%

Here's what is working for Modalis Therapeutics Corp.

Debt-Equity Ratio

Lowest at -111 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Modalis Therapeutics Corp.

Interest

At JPY 6.95 MM has Grown at inf%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Pre-Tax Profit

At JPY -615.07 MM has Fallen at -35.23%

over average net sales of the previous four periods of JPY -454.83 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (JPY MM)

Net Profit

At JPY -621.36 MM has Fallen at -36.49%

over average net sales of the previous four periods of JPY -455.26 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)